Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W7D4 | ISIN: CA05156V1022 | Ticker-Symbol: IKAP
Tradegate
19.11.24
18:35 Uhr
7,558 Euro
-0,266
-3,40 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
AURINIA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AURINIA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,7007,88615:03
7,7187,88415:03

Aktuelle News zur AURINIA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.11.Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets2
07.11.Aurinia stock jumps 14% on Q3 earnings, restructuring announcement4
07.11.More turbulence at Aurinia as autoimmune drugmaker lays off 45% of workforce3
07.11.Aurinia Pharma GAAP EPS of $0.10 beats by $0.09, revenue of $67.77M beats by $10.08M5
07.11.Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development87ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months...
► Artikel lesen
07.11.Aurinia Pharmaceuticals Inc. - 10-Q, Quarterly Report-
07.11.Aurinia Pharmaceuticals Inc. - 8-K, Current Report-
06.11.Aurinia Pharma Q3 2024 Earnings Preview2
AURINIA PHARMACEUTICALS Aktie jetzt für 0€ handeln
11.10.Aurinia Pharmaceuticals spotlights lupus nephritis drug8
28.09.Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 13.0%2
24.09.Aurinia Announces Approval Of LUPKYNIS In Japan8
24.09.Japan approves Aurinia's lupus nephritis treatment1
13.09.Aurinia Pharmaceuticals shares gain as co reports Board restructuring5
12.09.Aurinia Pharmaceuticals strukturiert Vorstand um und beruft neuen Direktor3
12.09.Aurinia Pharmaceuticals reshuffles board, adds new director1
12.09.Aurinia Pharmaceuticals Inc. - 8-K, Current Report1
06.09.H.C. Wainwright reiterates Buy rating on Aurinia Pharma shares7
13.08.Investor activism resurfaces at Aurinia after CEO's board role, exec pay lost majority support7
13.08.On behalf of Lucien Selce: Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board347Highlights Damning Annual General Meeting Results, Which Show That Four of the Company's Nine Directors Failed to Receive a Majority of the Votes Calls on the Company to Appoint Two Shareholder...
► Artikel lesen
01.08.Earnings call: Aurinia Pharmaceuticals sees 38% revenue growth in Q25
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1